Shares of Prothena Corporation PRTA plummeted 53.5% year to date compared with the industry’s decline of 0.6%. The recent ...

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

The Business Research Company The Business Research Company's Asperger Syndrome Market 2025: Strategic Insights for Business Growth, Expans ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 25 stocks Jim Cramer recently shared insights on. While discussing drug ...

Bristol-Myers Squibb announced promising progress on its Phase 2 Alzheimer’s clinical trial of BMS-986446, an experimental ...